½ÃÀ庸°í¼­
»óǰÄÚµå
1570831

¼¼°èÀÇ µ¿¹°¿ë ÀǾàǰ Á¶Á¦ ½ÃÀå : Á¦Ç°º°, Çüź°, Åõ¿©º°, µ¿¹°º°, ÃÖÁ¾ »ç¿ëÀÚº° - ¿¹Ãø(2025-2030³â)

Animal Drug Compounding Market by Product (Anti-Infective Agents, Anti-Inflammatory Agents, Central Nervous System (CNS) Agents), Form (Capsules, Creams & Gels, Ointments), Administration, Animal, End-User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 195 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

µ¿¹°¿ë ÀǾàǰ Á¶Á¦ ½ÃÀåÀº 2023³â¿¡ 11¾ï 9,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 12¾ï 8,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, CAGR 9.98%·Î ¼ºÀåÇÒ Àü¸ÁÀ̰í, 2030³â¿¡´Â 23¾ï 3,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

µ¿¹°¿ë ÀǾàǰ Á¶Á¦¶õ, ½ÃÆÇµÇ´Â ÀǾàǰÀ¸·Î´Â ºÒÃæºÐÇÑ °æ¿ì¿¡, ƯÁ¤ÀÇ ¿ä±¸³ª »óȲ¿¡ ¸ÂÃß¾î µ¿¹°¿ëÀ¸·Î Ä¿½ºÅ͸¶ÀÌÁîÇü ÀǾàǰÀ» Á¶Á¦ÇÏ´Â °ÍÀ» ¸»ÇÕ´Ï´Ù. µ¿¹°ÀÇ Å©±â, À¯Çü ¹× ƯÁ¤ °Ç°­ ¿ä±¸ »çÇ×Àº ´Ù¾çÇϸç Ç¥ÁØ ¾à¹°·Î´Â ´ëÀÀÇÒ ¼ö ¾ø±â ¶§¹®¿¡ ÀÌ·¯ÇÑ °üÇàÀÌ ÇÊ¿äÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, ¸»°ú °°Àº ´ëÇü µ¿¹°Àº °í¾çÀÌ¿Í °³¿Í °°Àº ¼ÒÇü µ¿¹°°ú ´Ù¸¥ ¿ë·®À» ÇÊ¿ä·Î ÇÒ ¼ö ÀÖÀ¸¸ç, ƯÁ¤ Á¦Çü°ú Çâ·á¿¡ ¾Ë·¹¸£±â ¹ÝÀÀÀ» ³ªÅ¸³»´Â µ¿¹°µµ ÀÖ½À´Ï´Ù. ÁÖ¿ä ¿ëµµ·Î´Â º¹¿ë·® º¯°æ, º¹¿ë ÇüÅ º¯°æ(ÅÂºí¸´¿¡¼­ ¾×ü·ÎÀÇ º¯°æ µî), ¾à¹°À» ´õ ¼±È£ÇÏ´Â °ÍÀ¸·Î ¸¸µå´Â Çâ·á ÷°¡ µîÀÌ ÀÖ½À´Ï´Ù. ÃÖÁ¾ ¿ëµµ´Â µ¿¹° º´¿ø, µ¿¹° º´¿ø, °¡Ãà °ü¸® ½Ã¼³ µîÀÔ´Ï´Ù. ½ÃÀåÀÇ ¼ºÀåÀº ¼¼°è ¹Ý·Áµ¿¹° »çÀ° Áõ°¡, µ¿¹°ÀÇ ¸¸¼º Áúȯ Áõ°¡, µ¿¹° ÀÇÇп¡¼­º¸´Ù °³ÀÎÈ­µÈ ÀÇ·áÀÇ Çʿ伺¿¡ ¿µÇâÀ» ¹Þ½À´Ï´Ù. °Ô´Ù°¡, ÀǾà Á¦ÇüÀÇ Áøº¸´Â º¸´Ù Á¤È®Çϰí È¿°úÀûÀÎ Á¦Á¦¸¦ °¡´ÉÇÏ°Ô Çϰí, Ãß°¡ ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ÇöÀçÀÇ ºñÁî´Ï½º ±âȸ¿¡´Â µ¿¹° ÀÇ·á°¡ ¼ºÀåÇϰí ÀÖ´Â ½ÅÈï ½ÃÀåÀ¸·ÎÀÇ ÁøÃâ°ú º¸´Ù Á¤È®ÇÑ Ã³¹æÀ» À§ÇÑ ±â¼úÀÇ È°¿ë µîÀÌ ÀÖ½À´Ï´Ù. ±×·¯³ª FDA¿Í °°Àº ±â°ü¿¡ ÀÇÇÑ ±ÔÁ¦ Àå¾Ö¹°°ú ¾ö°ÝÇÑ Ç°Áú°ü¸®±âÁØ À¯Áö µî ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ´Â °úÁ¦µµ ³²¾Æ ÀÖ½À´Ï´Ù. ´Ù¾çÇÑ »ý¹°Á¾¿¡ ´ëÇÑ ÀǾàǰÀÇ ¾ÈÀü¼º°ú È¿´ÉÀ» º¸ÀåÇÏ´Â º¹À⼺Àº ½ÃÀå È®´ë¸¦ ´õ¿í º¹ÀâÇÏ°Ô ¸¸µì´Ï´Ù. ±â¼ú Çõ½ÅÀº º¸´Ù È¿À²ÀûÀÎ Á¦Çü °øÁ¤ ±¸Ãà, ȯ°æ ģȭÀûÀÌ°í ¾ÈÀüÇÑ Á¦Çü °³¹ß, º¸´Ù Á¤È®ÇÑ Åõ¾àÀ» À§ÇÑ µðÁöÅÐ µµ±¸ÀÇ È°¿ë µîÀ» Áß½ÉÀ¸·Î Àü°³ÇÒ ¼ö ÀÖ½À´Ï´Ù. ´ëü Á¶Á¦ Àç·á¿Í ºÎÁ¤ °³ºÀ ¹æÁö Æ÷Àå Á¶»çµµ °æÀï ¿ìÀ§¸¦ °¡Á®¿Ã ¼ö ÀÖ½À´Ï´Ù. ¿¬±¸°³¹ßÀ» À§ÇØ ¼öÀÇÇбâ°ü°ú °øµ¿ ÆÄÆ®³Ê½ÊÀ» ¸ÎÀ½À¸·Î½á Áß¿äÇÑ ÀλçÀÌÆ®¸¦ ¾ò°í ½ÃÀåÀÇ ¹Ø´ÜÀÌ ³Ð¾îÁú ¼ö ÀÖ½À´Ï´Ù. ±Ã±ØÀûÀ¸·Î, °³º°È­µÈ µ¿¹° °ü¸®¿Í ¼¼°è È®Àå Àü·«¿¡ ÃÊÁ¡À» ¸ÂÃß´Â °ÍÀÌ ½ÃÀå ¸®´õ¿¡°Ô ¸Å¿ì Áß¿äÇÏ´Ù´Â °ÍÀÌ ÀÔÁõµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023³â) 11¾ï 9,000¸¸ ´Þ·¯
¿¹Ãø³â(2024³â) 12¾ï 8,000¸¸ ´Þ·¯
¿¹Ãø³â(2030³â) 23¾ï 3,000¸¸ ´Þ·¯
CAGR(%) 9.98%

½ÃÀå ¿ªÇÐ : ºü¸£°Ô ÁøÈ­ÇÏ´Â µ¿¹°¿ë ÀǾàǰ Á¶Á¦ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

µ¿¹°¿ë ÀǾàǰ Á¶Á¦ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÅõÀÚ°áÁ¤, Àü·«Àû °áÁ¤ Á¤¹ÐÈ­, »õ·Î¿î ºñÁî´Ï½º ±âȸ ȹµæ¿¡ ´ëºñÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦ÀûÀÎ ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖ¾î, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¶Ç´Â ±¸¸Å Ãß¼¼¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇØ ´õ ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

Portre's Five Forces : µ¿¹°¿ë ÀǾàǰ Á¶Á¦ ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces ÇÁ·¹ÀÓ ¿öÅ©´Â ±â¾÷ÀÇ °æÀïÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ޱ¸ÇÏ´Â ¸íÈ®ÇÑ ±â¼úÀ» ¼³¸íÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» °áÁ¤ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®¸¦ ÅëÇØ ±â¾÷Àº ÀÚ»çÀÇ °­Á¡À» Ȱ¿ëÇÏ°í ¾àÁ¡À» ÇØ°áÇϰí ÀáÀçÀûÀÎ °úÁ¦¸¦ ÇÇÇÒ ¼ö ÀÖÀ¸¸ç º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : µ¿¹°¿ë ÀǾàǰ Á¶Á¦ ½ÃÀå¿¡¼­ ¿ÜºÎ·ÎºÎÅÍÀÇ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº µ¿¹°¿ë ÀǾàǰ Á¶Á¦ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ ¼³¸íÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¾ÕÀ¸·Î ¿¹»óµÇ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : µ¿¹°¿ë ÀǾàǰ Á¶Á¦ ½ÃÀå¿¡¼­ °æÀï ±¸µµ ÆÄ¾Ç

µ¿¹°¿ë ÀǾàǰ Á¶Á¦ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï Æ÷Áö¼Å´×À» ¹àÈú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ¼¼ºÐÈ­ ¹× ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í °ø±Þ¾÷ü´Â °æÀïÀÌ Ä¡¿­ÇØÁö¸é¼­ ÀÚ½ÅÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : µ¿¹°¿ë ÀǾàǰ Á¶Á¦ ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â µ¿¹°¿ë ÀǾàǰ Á¶Á¦ ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ Çà·ÄÀ» ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °ø±Þ¾÷üÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ¸Â´Â ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ºÎ¹®È­Çϰí Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ : µ¿¹°¿ë ÀǾàǰ Á¶Á¦ ½ÃÀå¿¡¼­ ¼º°øÀ» À§ÇÑ ±æ ±×¸®±â

µ¿¹°¿ë ÀǾàǰ Á¶Á¦ ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÇÁ·¹Á𽺠°­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í °³¼±À» À§ÇØ ³ë·ÂÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ Á¢±Ù¹ýÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ¸¶·ÃÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â Á¾ÇÕÀûÀÎ ½ÃÀå ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æ¿¡ ´ëÇØ »ó¼¼È÷ °ËÅäÇÕ´Ï´Ù.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÎ¹®¿¡¼­ÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» ¼³¸íÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ°í ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» Á¶»çÇß½À´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, ¿¬±¸°³¹ß Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡µµ ´äº¯Çϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð ¹× ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ ¹× ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À² ¹× °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ¹Ý·Áµ¿¹°ÀÇ »çÀ°¼ö°¡ ¼¼°èÀûÀ¸·Î Áõ°¡ÇØ, ¹Ý·Áµ¿¹° ¼ÒÀ¯ÀÚ°¡ ¹Ý·Áµ¿¹°¿¡ µ·À» »ç¿ëÇÏ´Â ÀÇ¿å °íÁ¶
      • ¹Ý·Áµ¿¹°ÀÇ ¸¸¼º Áúȯ Áõ°¡¿Í ƯÁ¤ ¾à¹°ÀÇ Çʿ伺
      • ¼¼°è µ¿¹°¿ë Ŭ¸®´Ð°ú ¾à±¹ È®´ë
    • ¾ïÁ¦¿äÀÎ
      • Á¶ÇÕ °øÁ¤ÀÇ º¹À⼺°ú ¼÷·ÃµÈ ÀοøÀÇ Çʿ伺
    • ±âȸ
      • ¼öÀÇÇÐ ÀÌÇÐÀÇ Çõ½Å°ú ¾à¹°Àü´Þ ±â¼úÀÇ Áøº¸
      • µ¿¹° º´¿ø, ¹Ý·Áµ¿¹° º¸Çè ȸ»ç, ¿¬±¸ ±â°ü°úÀÇ Àü·«Àû Á¦ÈÞ ±¸Ãà
    • °úÁ¦
      • µ¿¹°¿ë ÀǾàǰ Á¶Á¦ÀÇ ¾ÈÀü¼º°ú È¿´É¿¡ °üÇÑ ¿ì·Á
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
    • Á¦Ç°º° : ¿°Áõ¼º ÁúȯÀÇ ¸¸¿¬¿¡ ´ëÀÀÇÏ´Â Ç׿°ÁõÁ¦ÀÇ Çʿ伺
    • ÃÖÁ¾ »ç¿ëÀÚº° : ¼öÀÇ»ç Ŭ¸®´Ð°ú º´¿ø¿¡¼­ Ä¡·áµÇ´Â ´Ù¾çÇÑ Á¾°ú ´Ù¾çÇÑ º´¸®
  • Porter's Five Forces ºÐ¼®
  • PESTLE ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå µ¿¹°¿ë ÀǾàǰ Á¶Á¦ ½ÃÀå : Á¦Ç°º°

  • ¼­¹®
  • Ç×°¨¿°Á¦
  • Ç׿°ÁõÁ¦
  • ÁßÃ߽Űæ°è(CNS)¾à
  • À§Àå¾à

Á¦7Àå µ¿¹°¿ë ÀǾàǰ Á¶Á¦ ½ÃÀå : Çüź°

  • ¼­¹®
  • ĸ½¶
  • Å©¸² ¹× Á©
  • ¿¬°í
  • Çöʾ×

Á¦8Àå µ¿¹°¿ë ÀǾàǰ Á¶Á¦ ½ÃÀå : Åõ¿©º°

  • ¼­¹®
  • ÁÖ»ç
  • °æ±¸
  • ±¹¼Ò

Á¦9Àå µ¿¹°¿ë ÀǾàǰ Á¶Á¦ ½ÃÀå : µ¿¹°º°

  • ¼­¹®
  • ¹Ý·Á µ¿¹°
  • ´ëÇü µ¿¹°
  • °¡Ãà

Á¦10Àå µ¿¹°¿ë ÀǾàǰ Á¶Á¦ ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • ¼­¹®
  • ¼ÒÀÇ »çÀ°
  • ¹Ý·Á µ¿¹° ÁÖÀÎ
  • ¾ç°è¾÷
  • µ¿¹°¿ë Ŭ¸®´Ð ¹× º´¿ø

Á¦11Àå ¾Æ¸Þ¸®Ä«ÀÇ µ¿¹°¿ë ÀǾàǰ Á¶Á¦ ½ÃÀå

  • ¼­¹®
  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦12Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ µ¿¹°¿ë ÀǾàǰ Á¶Á¦ ½ÃÀå

  • ¼­¹®
  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦13Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ µ¿¹°¿ë ÀǾàǰ Á¶Á¦ ½ÃÀå

  • ¼­¹®
  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦14Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º(2023³â)
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
    • Surescripts¿Í DAW SystemsÀÇ Àü·«Àû Á¦ÈÞ·Î ¼öÀÇ»çÀÇ ÀüÀÚ Ã³¹æÀÌ °­È­µÇ¾î ¹Ý·Áµ¿¹° Äɾ À־ÀÇ È¿À²°ú º¹¾à Áؼö Çâ»ó
    • MixlabÀÌ Vanterra VenturesÀÇ Áö¿øÀ» ¹Þ¾Æ NexGen Animal Health¸¦ ÀμöÇÏ¿© ´ëÇü µ¿¹°¿¡ ´ëÇÑ Á¶ÇÕ ¼­ºñ½º È®´ë
    • Veterinary Pharmaceutical Solutions, Diamond Animal HealthÀÇ Àμö¿¡ ÀÇÇØ ½ÃÀå¿¡¼­ÀÇ ÁöÀ§ °­È­
  • Àü·« ºÐ¼® ¹× Á¦¾È
AJY 24.10.31

The Animal Drug Compounding Market was valued at USD 1.19 billion in 2023, expected to reach USD 1.28 billion in 2024, and is projected to grow at a CAGR of 9.98%, to USD 2.33 billion by 2030.

Animal drug compounding refers to the customized preparation of medications for animals, tailored to specific needs and circumstances when commercially available drugs do not suffice. This practice is necessary due to the varied sizes, species, and specific health needs of animals, which standard forms of medication may not fulfill. For instance, large animals like horses may require a different dose compared to smaller animals such as cats or dogs, and some animals may have allergic reactions to certain formulations or flavors. The primary applications include altering drug dosages, changing medication formats (such as from a pill to a liquid), and adding flavors to make medications more palatable. End-use scopes encompass veterinary clinics, animal hospitals, and livestock management facilities. Market growth is influenced by the increasing pet ownership globally, the rise of chronic diseases in animals, and the need for more personalized medicine in veterinary care. Moreover, advancements in pharmaceutical formulations have enabled more precise and effective compounded drugs, driving further demand. Current opportunities include expanding into emerging markets where veterinary health care is growing, and leveraging technology for more accurate formulations. However, challenges persist, including regulatory hurdles imposed by agencies like the FDA and maintaining stringent quality control standards, which can inhibit growth. The complexity of ensuring drug safety and efficacy for varied species further complicates market expansion. Innovations can revolve around creating more efficient compounding processes, developing eco-friendly and safe formulations, and utilizing digital tools for better dosage accuracy. Research into alternative compounding materials and tamper-proof packaging may also offer competitive advantages. Entering collaborative partnerships with veterinary institutions for research and development could provide critical insights and broaden the market reach. Ultimately, a focus on personalized animal care and global expansion strategies could prove pivotal for market leaders.

KEY MARKET STATISTICS
Base Year [2023] USD 1.19 billion
Estimated Year [2024] USD 1.28 billion
Forecast Year [2030] USD 2.33 billion
CAGR (%) 9.98%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Animal Drug Compounding Market

The Animal Drug Compounding Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in pet ownership globally, coupled with the growing willingness of pet owners to spend on their pets
    • Increase in chronic conditions in pets and need for specific medications
    • Expansion of veterinary clinics and pharmacies across the world
  • Market Restraints
    • Complexities in the compounding process and the need for skilled personnel
  • Market Opportunities
    • Innovations in veterinary pharmacology and advancements in drug delivery technologies
    • Establishment of strategic alliances with veterinary clinics, animal hospitals, pet insurance companies, and research institutions
  • Market Challenges
    • Concerns related to the safety and efficacy of animal drug compounding

Porter's Five Forces: A Strategic Tool for Navigating the Animal Drug Compounding Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Animal Drug Compounding Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Animal Drug Compounding Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Animal Drug Compounding Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Animal Drug Compounding Market

A detailed market share analysis in the Animal Drug Compounding Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Animal Drug Compounding Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Animal Drug Compounding Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Animal Drug Compounding Market

A strategic analysis of the Animal Drug Compounding Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Animal Drug Compounding Market, highlighting leading vendors and their innovative profiles. These include Akina Animal Health, Aurora Compounding Pharmacy, Caringbah Compounding Pharmacy, Central Compounding Center South, Chiron Compounding Pharmacy, Inc, Custom-Med Compounding Pharmacy, Davis Islands Pharmacy, Dougherty's Pharmacy, Inc, Hoye's Pharmacy, Medisca Inc., MEDS Canadian Compounding Pharmacy, Millers Pharmacy, Pace Pharmacy, People's Choice of Pharmacy, Pratt's Compounding Pharmacy, Sixth Avenue Medical Pharmacy, Smith Caldwell Drug Store by Walgreen Co., Specialist Compounding Pharmacy Pte Ltd, Tache Pharmacy & Medical Supplies, Triangle Compounding Pharmacy, Vertisis Custom Pharmacy, Victoria Compounding Pharmacy, Vimian Group AB, Wedgewood Pharmacy, and Wellness Pharmacy of Cary.

Market Segmentation & Coverage

This research report categorizes the Animal Drug Compounding Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Anti-Infective Agents, Anti-Inflammatory Agents, Central Nervous System (CNS) Agents, and Gastro-Intestinal(GI) Drugs.
  • Based on Form, market is studied across Capsules, Creams & Gels, Ointments, and Suspension.
  • Based on Administration, market is studied across Injectable, Oral, and Topical.
  • Based on Animal, market is studied across Companion Animals, Large Animals, and Livestock Animals.
  • Based on End-User, market is studied across Cattle Rearing, Pet Owners, Poultry Businesses, and Veterinary Clinics & Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in pet ownership globally, coupled with the growing willingness of pet owners to spend on their pets
      • 5.1.1.2. Increase in chronic conditions in pets and need for specific medications
      • 5.1.1.3. Expansion of veterinary clinics and pharmacies across the world
    • 5.1.2. Restraints
      • 5.1.2.1. Complexities in the compounding process and the need for skilled personnel
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovations in veterinary pharmacology and advancements in drug delivery technologies
      • 5.1.3.2. Establishment of strategic alliances with veterinary clinics, animal hospitals, pet insurance companies, and research institutions
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns related to the safety and efficacy of animal drug compounding
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Need for anti-inflammatory agents to cater to the high prevalence of inflammatory conditions
    • 5.2.2. End-User: Extensive range of species and wide variety of medical conditions treated in veterinary clinics and hospitals
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Animal Drug Compounding Market, by Product

  • 6.1. Introduction
  • 6.2. Anti-Infective Agents
  • 6.3. Anti-Inflammatory Agents
  • 6.4. Central Nervous System (CNS) Agents
  • 6.5. Gastro-Intestinal(GI) Drugs

7. Animal Drug Compounding Market, by Form

  • 7.1. Introduction
  • 7.2. Capsules
  • 7.3. Creams & Gels
  • 7.4. Ointments
  • 7.5. Suspension

8. Animal Drug Compounding Market, by Administration

  • 8.1. Introduction
  • 8.2. Injectable
  • 8.3. Oral
  • 8.4. Topical

9. Animal Drug Compounding Market, by Animal

  • 9.1. Introduction
  • 9.2. Companion Animals
  • 9.3. Large Animals
  • 9.4. Livestock Animals

10. Animal Drug Compounding Market, by End-User

  • 10.1. Introduction
  • 10.2. Cattle Rearing
  • 10.3. Pet Owners
  • 10.4. Poultry Businesses
  • 10.5. Veterinary Clinics & Hospitals

11. Americas Animal Drug Compounding Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Animal Drug Compounding Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Animal Drug Compounding Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Strategic Partnership Between Surescripts and DAW Systems Enhances Veterinary e-Prescribing, Boosts Efficiency and Medication Adherence in Pet Care
    • 14.3.2. Mixlab Acquires NexGen Animal Health to Expand Compounding Services to Large Animals with Vanterra Ventures' Backing
    • 14.3.3. Veterinary Pharmaceutical Solutions Strengthens Market Position with Acquisition of Diamond Animal Health
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Akina Animal Health
  • 2. Aurora Compounding Pharmacy
  • 3. Caringbah Compounding Pharmacy
  • 4. Central Compounding Center South
  • 5. Chiron Compounding Pharmacy, Inc
  • 6. Custom-Med Compounding Pharmacy
  • 7. Davis Islands Pharmacy
  • 8. Dougherty's Pharmacy, Inc
  • 9. Hoye's Pharmacy
  • 10. Medisca Inc.
  • 11. MEDS Canadian Compounding Pharmacy
  • 12. Millers Pharmacy
  • 13. Pace Pharmacy
  • 14. People's Choice of Pharmacy
  • 15. Pratt's Compounding Pharmacy
  • 16. Sixth Avenue Medical Pharmacy
  • 17. Smith Caldwell Drug Store by Walgreen Co.
  • 18. Specialist Compounding Pharmacy Pte Ltd
  • 19. Tache Pharmacy & Medical Supplies
  • 20. Triangle Compounding Pharmacy
  • 21. Vertisis Custom Pharmacy
  • 22. Victoria Compounding Pharmacy
  • 23. Vimian Group AB
  • 24. Wedgewood Pharmacy
  • 25. Wellness Pharmacy of Cary
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦